原始来源记录
重大申请已提交
Metagenomi：MGX-001 IND提交计划于2026年第四季度
该公司确认其领先的血友病A项目仍按计划于2026年第四季度提交IND。该提交旨在使2027年开展首次人体研究，但需获得监管批准。
关键事实
来源摘录
EX-99.1 2 mgx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its p